Enanta Pharmaceuticals Inc (ENTA) Cut to Sell at Zacks Investment Research
Enanta Pharmaceuticals Inc (NASDAQ:ENTA) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Friday.
According to Zacks, “Enanta Pharmaceuticals, Inc. is a biotechnology company. It engages in the research and development of molecule drugs for the treatment of infectious diseases such as hepatitis C virus, respiratory tract infections, intravenous and oral treatments. Enanta Pharmaceuticals, Inc. is headquartered in Watertown, Massachusetts. “
Shares of Enanta Pharmaceuticals (NASDAQ:ENTA) traded down 0.06% during midday trading on Friday, hitting $33.31. 113,602 shares of the stock traded hands. The company’s market capitalization is $634.46 million. Enanta Pharmaceuticals has a 1-year low of $20.79 and a 1-year high of $37.31. The stock has a 50 day moving average of $30.95 and a 200 day moving average of $30.62.
Enanta Pharmaceuticals (NASDAQ:ENTA) last released its quarterly earnings data on Monday, May 8th. The biotechnology company reported ($0.28) earnings per share for the quarter, beating the consensus estimate of ($0.38) by $0.10. The business had revenue of $9 million for the quarter, compared to analyst estimates of $9.19 million. Enanta Pharmaceuticals had a negative return on equity of 3.54% and a negative net margin of 18.92%. Enanta Pharmaceuticals’s revenue was down 30.8% compared to the same quarter last year. During the same period last year, the firm posted ($0.09) earnings per share. Equities research analysts predict that Enanta Pharmaceuticals will post $0.02 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Enanta Pharmaceuticals Inc (ENTA) Cut to Sell at Zacks Investment Research” was originally posted by American Banking News and is the property of of American Banking News. If you are accessing this news story on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2017/05/12/enanta-pharmaceuticals-inc-enta-cut-to-sell-at-zacks-investment-research.html.
A number of hedge funds have recently added to or reduced their stakes in ENTA. BlackRock Fund Advisors raised its stake in Enanta Pharmaceuticals by 7.6% in the third quarter. BlackRock Fund Advisors now owns 1,293,604 shares of the biotechnology company’s stock valued at $34,423,000 after buying an additional 91,672 shares during the period. Vanguard Group Inc. raised its stake in Enanta Pharmaceuticals by 7.2% in the first quarter. Vanguard Group Inc. now owns 792,165 shares of the biotechnology company’s stock valued at $24,399,000 after buying an additional 53,007 shares during the period. Great Point Partners LLC acquired a new stake in Enanta Pharmaceuticals during the third quarter valued at $21,022,000. State Street Corp raised its stake in shares of Enanta Pharmaceuticals by 71.5% in the fourth quarter. State Street Corp now owns 568,238 shares of the biotechnology company’s stock worth $19,036,000 after buying an additional 236,871 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its stake in shares of Enanta Pharmaceuticals by 129.7% in the first quarter. Dimensional Fund Advisors LP now owns 413,089 shares of the biotechnology company’s stock worth $12,723,000 after buying an additional 233,265 shares during the last quarter. 71.61% of the stock is currently owned by institutional investors and hedge funds.
Enanta Pharmaceuticals Company Profile
Enanta Pharmaceuticals, Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Enanta Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.